OSE Immunotherapeutics - Collaboration bolsters upcoming Tedopi Phase III
OSE Immunotherapeutics (OSE) has announced a collaboration with GenDx for the development and validation of a companion diagnostic screening test...
219 Views
OSE Immunotherapeutics - Anticipation builds with positive OSE-279 data
At the AACR-NCI-EORTC conference in Boston, OSE presented the initial positive data supporting the potential efficacy of its anti-PD1 monoclonal...
216 Views
OSE Immunotherapeutics - Maintaining momentum after an active H123
OSE Immunotherapeutics (OSE) has announced its H123 results, providing an operational and a financial update. Highlights from the period included...
243 Views
OSE Immunotherapeutics - Publication puts Tedopi back in the spotlight
OSE has announced that the results from its Phase III trial (ATALANTE-1) for Tedopi have been published in Annals of Oncology. While the study...
364 Views
OSE Immunotherapeutics - Grant to weave RNA into R&D platform
OSE Immunotherapeutics (OSE) has announced that it has received grant innovation funding of €200,000 from the French government and Region Pays de...
301 Views